Moreover, modifiable risk factors at ICU discharge (e.g., anemia, hyperglycemia) as well as biomarker-guided interventions and follow-up using immunomodulation or cardiorenal protective treatments (e.g., renin–angiotensin–aldosterone system inhibitors) should be assessed in future sepsis-survivors trials with specific physiologic subtypes which are not necessarily associated with initial severity of illness. This evidence concerns the gene REN and anemia.